Can-Fite to Participate in Three Upcoming Pharma Partnering Conferences

Rhea-AI Summary

Can-Fite BioPharma Ltd (NYSE American: CANF) has secured approximately $20 million from partnering deals, with potential for an additional $130 million in milestone payments and royalties. The company will participate in three upcoming virtual conferences to meet with potential partners for its drug candidates targeting cancer, liver diseases, and inflammation. Key events include BioPharm America 2021 (Sept 20-23), TAP Diabetes 2021 (Oct 5-7), and BIO-Europe 2021 (Oct 25-29). Can-Fite's leading candidates are in advanced clinical stages.

Company has received ~$20 million to date from partnering deals with additional potential for up to $130 million, plus royalties based on milestones

PETACH TIKVA, Israel--(BUSINESS WIRE)-- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced its Vice President of Business of Development Dr. Sari Fishman will participate in three upcoming conferences to conduct meetings with potential development and commercialization partners for the Company’s portfolio of drug candidates.

Details are below:

BioPharm America 2021

Virtual Conference: part of Biotech Week Boston

Date: September 20 - 23, 2021

TAP Diabetes 2021

Virtual Conference: Therapeutics Area Partnership (TAP) specialized partnering event for diabetes

Date: October 5 - 7, 2021

BIO-Europe 2021

Virtual Conference: bringing global biopharma together to build partnerships that facilitate innovation

Date: October 25 - 29, 2021

Can-Fite currently has out-licensing agreements for its Namodenoson and Piclidenoson drug candidates in several territories and has received approximately $20 million in upfront and milestone payments to date with additional potential milestone payments of up to approximately $130 million, plus double-digit royalties on net sales following regulatory approval.

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, inflammatory disease and COVID-19. The Company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis and a Phase II study in the treatment of moderate COVID-19. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,500 patients in clinical studies to date. For more information please visit: www.can-fite.com.

Forward-Looking Statements

This press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, market risks and uncertainties, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of Can-Fite’s authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fite’s actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Can-Fite’s actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements. Factors that could cause our actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the impact of the COVID-19 pandemic; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; statements as to the impact of the political and security situation in Israel on our business; and risks and other risk factors detailed in Can-Fite’s filings with the SEC and in its periodic filings with the TASE. In addition, Can-Fite operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210917005024/en/

Can-Fite BioPharma

Motti Farbstein

info@canfite.com

+972-3-9241114

Source: Can-Fite BioPharma Ltd.

FAQ

What is the significance of the $20 million received by Can-Fite BioPharma (CANF)?

Can-Fite BioPharma has received approximately $20 million from partnering deals, with additional potential for up to $130 million in milestone payments.

Which conferences will Can-Fite BioPharma participate in during 2021?

Can-Fite BioPharma will participate in BioPharm America 2021 (Sept 20-23), TAP Diabetes 2021 (Oct 5-7), and BIO-Europe 2021 (Oct 25-29).

What are the drug candidates being developed by Can-Fite (CANF)?

Can-Fite is advancing drug candidates targeting cancer, liver diseases, and inflammatory diseases, including Piclidenoson and Namodenoson.

What milestones are associated with Can-Fite's drug candidates?

Can-Fite has milestone payments totaling up to approximately $130 million, plus royalties on net sales of their drugs post-approval.

What is the focus of Can-Fite BioPharma's pipeline?

Can-Fite's pipeline addresses major diseases including cancer, liver diseases, inflammatory conditions, and potential treatments for COVID-19.